https://www.selleckchem.com/products/gsk3787.html
For both assays, levels of ICs reflected active disease as determined by SLEDAI (r = 0.45, p less then 0.0001) and were associated with type I IFN activity (r = 0.37, p = 0.001), and complement consumption (p = 0.0002). Levels of ICs measured with IC-FLOW, but not with the commercial ELISA, were associated with active lupus nephritis (p = 0.004). Conclusions This novel FcγRIIA-IC assay can detect levels of circulating ICs in patients with SLE. Analyzing IC levels may facilitate monitoring of disease activity, as well as identify patient
Like
Comment
Share
